Clinical Trials List
2021-12-16 - 2029-12-31
Phase III
Recruiting5
ICD-10C54.1
Malignant neoplasm of endometrium
ICD-10C54.2
Malignant neoplasm of myometrium
ICD-10C54.3
Malignant neoplasm of fundus uteri
ICD-10C54.9
Malignant neoplasm of corpus uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9182.0
Malignant neoplasm of corpus uteri, except isthmus
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- Meng-Ru Shen 無
- Keng-Fu Hsu 無
- Cheng-Yang Chou 無
- 吳珮瑩 無
- 鄭雅敏 無
- 江佳蓉 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 童寶玲 無
- 戴依柔 無
- CHI-HAU CHEN CHI-HAU CHEN 無
- 郭冠廷 無
- Wen-Fang Cheng 未分科
- 陳宇立 無
- YING-CHENG CHIANG 無
- 施怡倫 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yi-Jen Chen 無
- 沈書慧 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
280 participants
